Theseus Pharmaceuticals Investor Relations Material
Latest events
Status Update
Theseus Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Theseus Pharmaceuticals Inc
Access all reports
Theseus Pharmaceuticals Inc., trading under the NASDAQ symbol THRX, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted therapies for cancer patients. The company's leading product candidate is THE-630, a pan-KIT inhibitor aimed at treating gastrointestinal stromal tumors. Additionally, Theseus is developing THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor intended for use in non-small cell lung cancer patients who have developed resistance to first- or later-line osimertinib treatment. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
THRX
Country
🇺🇸 United States